# Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology

> **NCT06417190** · PHASE2 · RECRUITING · sponsor: **Leslie Ballas** · enrollment: 20 (estimated)

## Conditions studied

- Muscle-Invasive Bladder Carcinoma
- Tumor

## Interventions

- **DRUG:** Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)

## Key facts

- **NCT ID:** NCT06417190
- **Lead sponsor:** Leslie Ballas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-16
- **Primary completion:** 2030-12
- **Final completion:** 2030-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06417190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06417190, "Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06417190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*